What question did this study set out to answer?

To evaluate the long-term benefits of the mRNA-based neoantigen vaccine in preventing melanoma recurrence or death.

February 5, 2026Cancer Discovery0 citations

Personalized Cancer Vaccine Shows Durable Benefit at 5 Years

Key Points

To evaluate the long-term benefits of the mRNA-based neoantigen vaccine in preventing melanoma recurrence or death.
Conducted a phase IIb trial (KEYNOTE-942)
Administered intismeran autogene with pembrolizumab
Followed participants for five years to assess outcomes
Reduced risk of melanoma recurrence or death by approximately 49%
Demonstrated durable benefits over a five-year period
Supports the use of personalized vaccine strategies in cancer treatment

Abstract

Five-year data from the phase IIb KEYNOTE-942 study show that the mRNA-based neoantigen vaccine intismeran autogene continues to reduce the risk of melanoma recurrence or death by roughly 49% when combined with pembrolizumab. This durability strengthens confidence in the personalized vaccine strategy, but a larger phase III trial will provide the decisive findings.

Perguntar à IA

Bookmark

View Full Paper

Cite This Study

A Mon, study studied this question.

synapsesocial.com/papers/6984359ef1d9ada3c1fb49de https://doi.org/https://doi.org/10.1158/2159-8290.cd-nw2026-0009